Table 1.
Characteristics of included studies (E: experimental group; C: control group).
| Num | Authors, publication year [reference] | Number of participants (% female) | Mean age (years) | Follow-up time (days) | Intervention | Outcomes | |
|---|---|---|---|---|---|---|---|
| Experimental group | Control group | ||||||
| 1 | Li Z et al. 2012 [22] | E: 30(28.33) C: 30(28.33) |
E: 61.3 C: 61.3 |
15 | Conventional treatment, Losartan potassium 50 mg, safflower yellow 100 mg | Conventional treatment∗, Losartan potassium 50 mg | ①②③④⑤ |
|
| |||||||
| 2 | Yang L H et al. 2010 [27] | E: 30(46.67) C: 30(40) |
E: 58.3 C: 58.6 |
14 | Conventional treatment, safflower yellow 100 mg | Conventional treatment | ①②③⑥ |
|
| |||||||
| 3 | Qiu T L et al. 2013 [23] | E: 42(42.86) C: 44(43.18) |
E: 51.6 ± 6.6 C: 52.7 ± 7.1 |
30 | Conventional treatment, safflower yellow 100 mg | Conventional treatment | ①②④⑤ |
|
| |||||||
| 4 | Gao Y et al. 2015 [16] | E: 60(45) C: 60(41.67) |
E: 64.6 ± 5.7 C: 65.0 ± 5.8 |
28 | Conventional treatment, Benazepril 10mg, safflower yellow 100 mg | Conventional treatment, Benazepril 10mg | ①③④⑤ |
|
| |||||||
| 5 | Bao X J. 2017 [28] | E: 40(45) C: 40(42.5) |
E: 50.45 ± 7.12 C: 49.74 ± 7.03 |
14 | Conventional treatment, Metformin 2g, safflower yellow 100 mg | Conventional treatment, Metformin 2g | ①②③④⑤⑥ |
|
| |||||||
| 6 | Zhang X Y. 2010 [29] | E: 36(47.22) C: 36(44.44) |
E: 62 C: 64 |
28 | Conventional treatment, Irbesartan 150mg, safflower yellow 100 mg | Conventional treatment, Irbesartan 150mg | ②③④⑤⑥ |
|
| |||||||
| 7 | Gao Y et al. 2015 [17] | E: 44(42) C: 44(42) |
E: 51.13 ± 7.42 C: 51.13 ± 7.42 |
28 | Conventional treatment, Telmisartan 80mg, safflower yellow 100 mg | Conventional treatment, Telmisartan 80mg | ②④⑤ |
|
| |||||||
| 8 | Xiao Y X. 2016 [30] | E: 40(47.5) C: 40(42.5) |
E: 58.9 ± 13.2 C: 59.5 ± 12.4 |
28 | Conventional treatment, safflower yellow 100 ml | Conventional treatment | ①②⑥ |
|
| |||||||
| 9 | Guo D Z. 2008 [18] | E: 37(48.65) C: 39(48.72) |
E: 46.9 ± 13.2 C: 47.3 ± 12.6 |
35 | Conventional treatment, Benazepril 10mg, safflower yellow 150mg | Conventional treatment, Benazepril 10mg | ①② |
|
| |||||||
| 10 | Zhang M H. 2013 [24] | E: 25(48) C: 25(48) |
E: 56 ± 8.6 C: 56 ± 8.6 |
28 | Conventional treatment, safflower yellow 150mg | Conventional treatment | ② |
|
| |||||||
| 11 | Fang Z F. 2015 [19] | E: 45(46.67) C: 45(51.11) |
E: 56.0 ± 7.9 C: 55.8 ± 7.6 |
8 weeks | Conventional treatment, Valsartan 80mg, safflower yellow 100 ml | Conventional treatment, Valsartan 80mg | ①②⑥ |
|
| |||||||
| 12 | Bai X M. 2012 [31] | E: 30(46.67) C: 30(46.67) |
E: 56 ± 7.9 C: 55.8 ± 7.6 |
30 | Conventional treatment, safflower yellow 200mg | Conventional treatment | ②③⑥ |
|
| |||||||
| 13 | Gao Y et al. 2015 [20] | E: 30(40) C: 30(40) |
E: 59.5 ± 12.4 C: 59.5 ± 12.4 |
30 | Conventional treatment, safflower yellow 100mg | Conventional treatment | ②④⑤⑥ |
|
| |||||||
| 14 | Shi Z M 2015 [21] | E: 45 (48.89) C: 45(48.89) |
51.5 51.5 |
12 weeks | Conventional treatment, Valsartan 80mg/d, safflower yellow 150mg | Conventional treatment, Valsartan 80mg/d | ②⑥ |
∗Conventional treatment includes diabetes education, diet, exercise, and glycemic and blood pressure control.
①Effective rate, % .
②UAER.
③FBG.
④Scr.
⑤BUN.
⑥Adverse event.